Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.22)
# 4,338
Out of 5,015 analysts
16
Total ratings
21.43%
Success rate
-30.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $3 | $0.30 | +884.57% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $2.00 | +700.00% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.87 | +381.28% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $2.29 | +249.34% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $15.27 | +554.88% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.20 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.38 | +39,228.79% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.27 | +359.12% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $4.80 | +337.50% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $87.82 | +2.48% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $3.93 | +7,788.04% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $4.15 | +809,538.55% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $3
Current: $0.30
Upside: +884.57%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $2.00
Upside: +700.00%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.87
Upside: +381.28%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $2.29
Upside: +249.34%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $15.27
Upside: +554.88%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.20
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.38
Upside: +39,228.79%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.27
Upside: +359.12%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $4.80
Upside: +337.50%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $87.82
Upside: +2.48%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $3.93
Upside: +7,788.04%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $4.15
Upside: +809,538.55%